1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,550 | 1,690 | 11:11 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05:06 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FDA ACCEPTANCE OF THE NDA FOR PIMICOTINIB FOR THE TREATMENT OF TGCT | 1 | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 02:42 | Abbisko Therapeutics Announces FDA Acceptance Of Pimicotinib NDA For Tenosynovial Giant Cell Tumor | 277 | AFX News | HONG KONG (dpa-AFX) - Abbisko Therapeutics Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA) for pimicotinib (ABSK021).... ► Artikel lesen | |
| 01:54 | Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor | 58 | PR Newswire | SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced... ► Artikel lesen | |
| 24.12.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE NMPA FOR ORAL SMALL MOLECULE KRAS G12D INHIBITOR ABSK141 | 5 | HKEx | ||
| 22.12.25 | Abbisko Therapeutics Co., Ltd.: Abbisko Therapeutics' CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor | 193 | GlobeNewswire (Europe) | Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world's first regulatory approval for pimicotinib, the first domestically... ► Artikel lesen | |
| 22.12.25 | ABBISKO-B (02256): INSIDE INFORMATION - ABBISKO THERAPEUTICS' CSF-1R INHIBITOR PIMICOTINIB APPROVED BY THE CHINA NMPA | 3 | HKEx | ||
| 16.12.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING OF ABSK061, FGFR2/3 INHIBITOR, FOR THE TREATMENT OF ACHONDROPLASIA | 1 | HKEx | ||
| 08.12.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS PRELIMINARY PHASE II RESULTS OF ORAL PD-L1 INHIBITOR ABSK043 COMBINED WITH EGFR ... | 1 | HKEx | ||
| 01.12.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE FDA FOR ORAL SMALL MOLECULE KRAS G12D INHIBITOR ABSK141 | 1 | HKEx | ||
| 17.11.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER STUDY OF PIMICOTINIB ... | 1 | HKEx | ||
| 03.11.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING IN A PHASE II STUDY OF ABSK043, AN ORAL SMALL-MOLECULE ... | 1 | HKEx | ||
| 27.10.25 | Goldman Sachs initiates Abbisko Therapeutics stock with Buy rating | 3 | Investing.com | ||
| 27.10.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED PRECLINICAL FINDINGS ON NOVEL CDK4/2 INHIBITOR AND SMARCA2 PROTAC DEGRADER ... | 1 | HKEx | ||
| 20.10.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER TRIAL OF PIMICOTINIB ... | 1 | HKEx | ||
| 29.09.25 | ABBISKO-B (02256): GRANT OF OPTIONS UNDER THE POST-IPO SHARE OPTION SCHEME AND GRANT OF RSUS UNDER THE 2019 SHARE INCENTIVE PLAN | 1 | HKEx | ||
| 15.09.25 | ABBISKO-B (02256): 2025 INTERIM REPORT | 3 | HKEx | ||
| 28.08.25 | ABBISKO-B (02256): DISCLOSEABLE TRANSACTION - SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| 27.08.25 | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 20.08.25 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE CDE FOR ABBISKO THERAPEUTICS' ORAL PD-L1 INHIBITOR ABSK043 IN COMBINATION WITH KRAS ... | 1 | HKEx | ||
| 20.08.25 | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,35 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BEAM THERAPEUTICS | 33,690 | 0,00 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| BIODESIX | 8,080 | 0,00 % | Biodesix, Inc.: Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) | Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025.... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,040 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| ARCUTIS BIOTHERAPEUTICS | 26,780 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 23,720 | -2,31 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 32,980 | 0,00 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| VERA THERAPEUTICS | 46,460 | 0,00 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ALUMIS | 21,090 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| CG ONCOLOGY | 53,73 | 0,00 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,080 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,935 | 0,00 % | ADMA Biologics reports FY 2025 revenue in line with estimate, provides 2026-2029 outlook | ||
| APOGEE THERAPEUTICS | 77,65 | 0,00 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,830 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,330 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen |
ABBISKO CAYMAN LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,67 % bei einem Aktienkurs von 1,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.